In our opinion, a unified nomenclature should not only encompass the complex clinical and pathological features associated with RYR1 variations (including conditions that do not exhibit an overt myopathy such as MH susceptibility and exertional rhabdomyolysis), but also both accommodate future RYR1-related phenotypes and navigate the field away from utilizing non-specific histopathologic eponyms (Fig. 3). The gene discussed is RYR1; the disease is myopathy.